{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMC114%2Frtv&page=2", "query": { "intervention": "TMC114/rtv", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=TMC114%2Frtv&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T19:31:51.473Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00708162", "title": "Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infection" ], "interventions": [ { "name": "Elvitegravir", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "EVG placebo", "type": "DRUG" }, { "name": "RAL placebo", "type": "DRUG" }, { "name": "Background regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 724, "start_date": "2008-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-30", "last_synced_at": "2026-09-27T19:31:51.473Z", "location_count": 94, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 59 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00708162" }, { "nct_id": "NCT01605084", "title": "Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI Backbone", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Optimized NRTI backbone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2012-06-30", "completion_date": "2014-08-31", "has_results": false, "last_update_posted_date": "2023-12-19", "last_synced_at": "2026-09-27T19:31:51.473Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01605084" }, { "nct_id": "NCT01232361", "title": "IMPAACT P1080: Psychiatric and Antiretroviral Medication Concentrations in HIV-infected and Uninfected Children and Adolescents", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "ADHD", "HIV" ], "interventions": [], "intervention_types": [], "sponsor": "International Maternal Pediatric Adolescent AIDS Clinical Trials Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "6 Years to 25 Years" }, "enrollment_count": 127, "start_date": "2010-10-08", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2021-08-03", "last_synced_at": "2026-09-27T19:31:51.473Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Long Beach, California • Los Angeles, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01232361" }, { "nct_id": "NCT00677300", "title": "Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Raltegravir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dallas VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 85, "start_date": "2009-01", "completion_date": "2012-12", "has_results": false, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-09-27T19:31:51.473Z", "location_count": 2, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00677300" }, { "nct_id": "NCT04630002", "title": "Drug-drug Interaction (DDI) Study of GSK3640254 With Darunavir/Ritonavir (DRV/RTV) and Etravirine (ETR)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "Darunavir/Ritonavir (DRV/RTV)", "type": "DRUG" }, { "name": "Etravirine (ETR)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 54, "start_date": "2020-10-28", "completion_date": "2021-10-02", "has_results": true, "last_update_posted_date": "2024-08-29", "last_synced_at": "2026-09-27T19:31:51.473Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04630002" }, { "nct_id": "NCT00877591", "title": "Interaction of Buprenorphine With HIV Medications and Tuberculosis Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Opioid Dependency", "HIV Infections" ], "interventions": [ { "name": "Fosamprenavir/Ritonavir", "type": "DRUG" }, { "name": "Darunavir/Ritonavir", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Rifabutin", "type": "DRUG" }, { "name": "Buprenorphine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2008-04", "completion_date": "2013-04", "has_results": false, "last_update_posted_date": "2014-05-06", "last_synced_at": "2026-09-27T19:31:51.473Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877591" }, { "nct_id": "NCT02771249", "title": "Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infected Population With Latent Tuberculosis" ], "interventions": [ { "name": "rifapentene (RPT)", "type": "DRUG" }, { "name": "darunavir/cobicistat (DRV/c)", "type": "DRUG" }, { "name": "Isoniazid (INH)", "type": "DRUG" }, { "name": "Pyridoxine", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2016-06-03", "completion_date": "2021-08-17", "has_results": false, "last_update_posted_date": "2022-04-18", "last_synced_at": "2026-09-27T19:31:51.473Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02771249" }, { "nct_id": "NCT01199731", "title": "Dose-finding Study of GSK2248761 in Antiretroviral Therapy-experienced Subjects With NNRTI-resistant HIV Infection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "GSK2248761 100 mg once daily", "type": "DRUG" }, { "name": "GSK2248761 200 mg once daily", "type": "DRUG" }, { "name": "Etravirine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-10-05", "completion_date": "2011-07-19", "has_results": true, "last_update_posted_date": "2017-11-17", "last_synced_at": "2026-09-27T19:31:51.473Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01199731" }, { "nct_id": "NCT00884793", "title": "Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "raltegravir", "type": "DRUG" }, { "name": "Study NNRTI", "type": "DRUG" }, { "name": "Study PI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2008-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2012-07-23", "last_synced_at": "2026-09-27T19:31:51.473Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00884793" }, { "nct_id": "NCT00517192", "title": "Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Tipranavir", "type": "DRUG" }, { "name": "Darunavir", "type": "DRUG" }, { "name": "Ritonavir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2007-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-05-14", "last_synced_at": "2026-09-27T19:31:51.473Z", "location_count": 9, "location_summary": "Beverly Hills, California • Fort Lauderdale, Florida • Miami, Florida + 5 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00517192" } ] }